Suppr超能文献

识别可能从更短疗程治疗中获益的耐多药结核病患者。

Identifying patients with multidrug-resistant tuberculosis who may benefit from shorter durations of treatment.

机构信息

Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Canada.

Faculty of Pharmacy, Université de Montréal, Montreal, Canada.

出版信息

PLoS One. 2023 Oct 5;18(10):e0292106. doi: 10.1371/journal.pone.0292106. eCollection 2023.

Abstract

OBJECTIVE

Studying treatment duration for rifampicin-resistant and multidrug-resistant tuberculosis (MDR/RR-TB) using observational data is methodologically challenging. We aim to present a hypothesis generating approach to identify factors associated with shorter duration of treatment.

STUDY DESIGN AND SETTING

We conducted an individual patient data meta-analysis among MDR/RR-TB patients restricted to only those with successful treatment outcomes. Using multivariable linear regression, we estimated associations and their 95% confidence intervals (CI) between the outcome of individual deviation in treatment duration (in months) from the mean duration of their treatment site and patient characteristics, drug resistance, and treatments used.

RESULTS

Overall, 6702 patients with successful treatment outcomes from 84 treatment sites were included. We found that factors commonly associated with poor treatment outcomes were also associated with longer treatment durations, relative to the site mean duration. Use of bedaquiline was associated with a 0.51 (95% CI: 0.15, 0.87) month decrease in duration of treatment, which was consistent across subgroups, while MDR/RR-TB with fluoroquinolone resistance was associated with 0.78 (95% CI: 0.36, 1.21) months increase.

CONCLUSION

We describe a method to assess associations between clinical factors and treatment duration in observational studies of MDR/RR-TB patients, that may help identify patients who can benefit from shorter treatment.

摘要

目的

使用观察性数据研究利福平耐药和耐多药结核病(MDR/RR-TB)的治疗持续时间在方法学上具有挑战性。我们旨在提出一种假设生成方法,以确定与治疗持续时间较短相关的因素。

研究设计和设置

我们对仅具有成功治疗结果的 MDR/RR-TB 患者进行了个体患者数据荟萃分析。使用多变量线性回归,我们估计了个体治疗持续时间偏差(以月为单位)与治疗地点和患者特征、药物耐药性和使用的治疗方法之间的结果之间的关联及其 95%置信区间(CI)。

结果

总体而言,来自 84 个治疗地点的 6702 名成功治疗结局的患者被纳入研究。我们发现,与治疗结局不良相关的常见因素也与治疗持续时间延长有关,相对于治疗地点的平均持续时间。使用贝达喹啉与治疗持续时间减少 0.51 个月(95%CI:0.15,0.87)相关,这在各亚组中是一致的,而氟喹诺酮类耐药的 MDR/RR-TB 与治疗持续时间延长 0.78 个月(95%CI:0.36,1.21)相关。

结论

我们描述了一种在 MDR/RR-TB 患者的观察性研究中评估临床因素与治疗持续时间之间关联的方法,这可能有助于识别可以从缩短治疗中受益的患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b03e/10553332/8e69b16ca90d/pone.0292106.g001.jpg

相似文献

1
Identifying patients with multidrug-resistant tuberculosis who may benefit from shorter durations of treatment.
PLoS One. 2023 Oct 5;18(10):e0292106. doi: 10.1371/journal.pone.0292106. eCollection 2023.
4
Update of drug-resistant tuberculosis treatment guidelines: A turning point.
Int J Infect Dis. 2023 May;130 Suppl 1:S12-S15. doi: 10.1016/j.ijid.2023.03.013. Epub 2023 Mar 12.
5
Principles of chemotherapy for tuberculosis in national tuberculosis programmes of low- and middle-income countries.
Indian J Tuberc. 2020 Dec;67(4S):S16-S22. doi: 10.1016/j.ijtb.2020.11.010. Epub 2020 Nov 28.
9
Transmission and Drug Resistance Genotype of Multidrug-Resistant or Rifampicin-Resistant Mycobacterium tuberculosis in Chongqing, China.
Microbiol Spectr. 2022 Oct 26;10(5):e0240521. doi: 10.1128/spectrum.02405-21. Epub 2022 Oct 10.

本文引用的文献

1
Initial experience with BPaL-based regimens to treat multidrug-resistant TB.
Int J Tuberc Lung Dis. 2023 Aug 1;27(8):649-650. doi: 10.5588/ijtld.23.0185.
5
Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.
N Engl J Med. 2022 Sep 1;387(9):810-823. doi: 10.1056/NEJMoa2119430.
8

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验